About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NBIX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Parti…
NCT05226780 · SCN8A Developmental and Epileptic Encephalopathy Syndrome
NBI-921352
NBIX
Neurocrine Biosciences
Phase 2Terminated8Nov 12, 2025Registry ↗
Nov 12, 2026Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)
NCT07934303 · Friedreich's Ataxia
NBIB-0000223
NBIX
Neurocrine Biosciences
Phase 1Not yet recruiting24Nov 2028Registry ↗
Nov 12, 2026Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462 · Tardive Dyskinesia
NBI-1065890, Placebo
NBIX
Neurocrine Biosciences
Phase 2Recruiting100Feb 2027Registry ↗
Nov 3, 2026Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Ass…
NCT04400331 · Chorea, Huntington
Valbenazine
NBIX
Neurocrine Biosciences
Phase 3Terminated
was completed
154Nov 5, 2025Registry ↗
Nov 2, 2026Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in…
NCT06966401 · Major Depressive Disorder
NBI-1065845
NBIX
Neurocrine Biosciences
Phase 3Recruiting850May 2029Registry ↗
Oct 22, 2026A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participant…
NCT07196501 · Major Depressive Disorder
Osavampator, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting550Jul 2028Registry ↗
Sep 30, 2026Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Class…
NCT07850739 · Congenital Adrenal Hyperplasia
NBIP-01435
NBIX
Neurocrine Biosciences
Phase 2Not yet recruiting36Mar 16, 2028Registry ↗
Sep 29, 2026An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Dis…
NCT07288320 · Bipolar I Disorder, Mania
NBI-1117568, Placebo
NBIX
Neurocrine Biosciences
Phase 2Recruiting150Feb 2028Registry ↗
Sep 25, 2026Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818 · Schizophrenia
NBI-1117568, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting560Jul 2029Registry ↗
Sep 25, 2026NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 · Schizophrenia
NBI-1117568
NBIX
Neurocrine Biosciences
Phase 3Recruiting600Dec 2031Registry ↗
Sep 25, 2026NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098 · Schizophrenia
NBI-1117568, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting284Nov 2027Registry ↗
Sep 22, 2026Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a B…
NCT07832383 · Alzheimer's Disease
NBI-1117567, Placebo
NBIX
Neurocrine Biosciences
Phase 2Not yet recruiting135May 2028Registry ↗
Sep 18, 2026A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia…
NCT07105111 · Schizophrenia, Schizoaffective Disorder
Valbenazine
NBIX
Neurocrine Biosciences
Phase 4Recruiting100Jun 2028Registry ↗
Aug 11, 2026NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatm…
NCT06911112 · Major Depressive Disorder
NBI-1065845, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting200Jul 2027Registry ↗
Aug 10, 2026NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatm…
NCT06963021 · Major Depressive Disorder
NBI-1065845, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting200Jul 2027Registry ↗
Jul 22, 2026Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333 · Schizophrenia
NBI-1117570, Placebo
NBIX
Neurocrine Biosciences
Phase 2Recruiting120Aug 2027Registry ↗
Jul 17, 2026A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846 · Major Depressive Disorder
NBI-1070770, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed73Jul 25, 2025Registry ↗
Jun 18, 2026Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Asso…
NCT06312189 · Chorea, Huntington
Valbenazine
NBIX
Neurocrine Biosciences
Phase 3Enrolling by invitation7Apr 2028Registry ↗
May 11, 2026Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915 · Congenital Adrenal Hyperplasia
Crinecerfont, Placebo
NBIX
Neurocrine Biosciences
Phase 3Active, not recruiting182Jul 19, 2023Registry ↗
Apr 29, 2026Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskines…
NCT05206513 · Dyskinesia, Cerebral Palsy
Placebo, Valbenazine
NBIX
Neurocrine Biosciences
Phase 3Completed86Oct 16, 2025Registry ↗
Mar 6, 2026NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 · Schizophrenia
NBI-1117568, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting284Oct 2027Registry ↗
Feb 13, 2026Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With…
NCT05301894 · Epileptic Encephalopathy, Continuous Spike and Wave During…
NBI-827104
NBIX
Neurocrine Biosciences
Phase 2Terminated19Jan 27, 2025Registry ↗
Feb 10, 2026Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatme…
NCT05110157 · Schizophrenia
Placebo, Valbenazine
NBIX
Neurocrine Biosciences
Phase 3Completed442Feb 4, 2025Registry ↗
Jan 16, 2026Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participan…
NCT05859698 · Schizophrenia, Schizoaffective Disorder
Valbenazine
NBIX
Neurocrine Biosciences
Phase 4Completed59Dec 27, 2024Registry ↗
Oct 29, 2025Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants W…
NCT06786624 · Major Depressive Disorder
NBI-1065845, Placebo
NBIX
Neurocrine Biosciences
Phase 3Recruiting200Jul 2027Registry ↗
Oct 16, 2025Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epilept…
NCT04873869 · SCN8A Developmental and Epileptic Encephalopathy Syndrome
NBI-921352, Placebo
NBIX
Neurocrine Biosciences
Phase 2Terminated8Mar 17, 2023Registry ↗
Sep 5, 2025Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epile…
NCT04625101 · Epileptic Encephalopathy, Continuous Spike and Wave During…
NBI-827104, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed24Aug 8, 2022Registry ↗
Jul 11, 2025Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111 · Schizophrenia
NBI-1117568, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed210Jul 10, 2024Registry ↗
Jul 2, 2025Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cogni…
NCT05182476 · Schizophrenia
Placebo, Luvadaxistat
NBIX
Neurocrine Biosciences
Phase 2Terminated216Jun 28, 2024Registry ↗
Feb 5, 2025Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classi…
NCT04806451 · Congenital Adrenal Hyperplasia
Crinecerfont, Placebo
NBIX
Neurocrine Biosciences
Phase 3Active, not recruiting103Mar 10, 2023Registry ↗
Jan 15, 2025Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MD…
NCT05203341 · Major Depressive Disorder
Placebo, NBI-1065845
NBIX
Neurocrine Biosciences
Phase 2Completed183Jan 10, 2024Registry ↗
Dec 10, 2024VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
NCT03562494 · Parkinson's Disease
VY-AADC02, Sham (Placebo) Surgery
NBIX
Neurocrine Biosciences
Phase 1Completed14Oct 30, 2024Registry ↗
Nov 12, 2024Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment…
NCT05654870 · Schizophrenia
Valbenazine, Placebo
NBIX
Neurocrine Biosciences
Phase 3Terminated8Nov 8, 2023Registry ↗
Sep 26, 2024A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti…
NCT05159908 · Focal Onset Seizure, Focal Onset Epilepsy
NBI-921352, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed101Aug 21, 2023Registry ↗
Jul 31, 2024Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhed…
NCT05165394 · Anhedonia, Major Depressive Disorder
Placebo, NBI-1065846
NBIX
Neurocrine Biosciences
Phase 2Completed93Jul 7, 2023Registry ↗
Jul 18, 2024Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatr…
NCT04045145 · CAH - Congenital Adrenal Hyperplasia
Crinecerfont
NBIX
Neurocrine Biosciences
Phase 2Completed8Jul 2, 2021Registry ↗
Apr 12, 2024Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure M…
NCT05493293 · Focal Onset Seizure, Focal Onset Epilepsy
NBI-921352
NBIX
Neurocrine Biosciences
Phase 2Terminated82Mar 11, 2024Registry ↗
Feb 28, 2024A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
NCT03382639 · Schizophrenia
Luvadaxistat, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed256Dec 29, 2020Registry ↗
Feb 28, 2024A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
NCT03359785 · Schizophrenia
Luvadaxistat, Matching Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed31Dec 21, 2020Registry ↗
Dec 22, 2023Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
NCT03733496 · Parkinson's Disease
NBIX
Neurocrine Biosciences
—Completed14Jul 18, 2023Registry ↗
Oct 11, 2023Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Hunti…
NCT04102579 · Chorea, Huntington
Valbenazine, Placebo
NBIX
Neurocrine Biosciences
Phase 3Completed128Oct 15, 2021Registry ↗
Nov 28, 2022Opicapone Treatment Initiation Open-Label Study
NCT04787965 · Parkinson Disease
Opicapone
NBIX
Neurocrine Biosciences
—Completed239Aug 4, 2022Registry ↗
Jul 12, 2022Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
NCT04880616 · Essential Tremor
NBI-827104, Placebo
NBIX
Neurocrine Biosciences
Phase 2Completed31May 25, 2022Registry ↗
May 17, 2022Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
NCT03530293 · Tourette Syndrome
Valbenazine, Placebo oral capsule
NBIX
Neurocrine Biosciences
Phase 2Terminated81Jul 16, 2019Registry ↗
May 3, 2022Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital…
NCT03525886 · CAH - Congenital Adrenal Hyperplasia
NBI-74788
NBIX
Neurocrine Biosciences
Phase 2Completed18Apr 7, 2020Registry ↗
Apr 19, 2022Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
NCT03732534 · Tourette Syndrome
NBI-98854
NBIX
Neurocrine Biosciences
Phase 2Terminated6Feb 18, 2019Registry ↗
Mar 21, 2022Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
NCT03065192 · Idiopathic Parkinson's Disease, Parkinson's Disease
VY-AADC01
NBIX
Neurocrine Biosciences
Phase 1Completed16Aug 10, 2021Registry ↗
Feb 23, 2022Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With…
NCT03444038 · Tourette Syndrome
Valbenazine
NBIX
Neurocrine Biosciences
Phase 2Completed85Jul 12, 2019Registry ↗
Jun 30, 2021A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharm…
NCT04234672 · Healthy Volunteers
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion
NBIX
Neurocrine Biosciences
Phase 1Completed6Apr 4, 2020Registry ↗
Jun 28, 2021Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Touret…
NCT03325010 · Tourette Syndrome
Valbenazine, Placebo oral capsule
NBIX
Neurocrine Biosciences
Phase 2Completed127Nov 1, 2018Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:04 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances